Literature DB >> 25310904

A soluble phosphodiesterase in Leishmania donovani negatively regulates cAMP signaling by inhibiting protein kinase A through a two way process involving catalytic as well as non-catalytic sites.

Amit Vij1, Arunima Biswas1, Arijit Bhattacharya2, Pijush K Das3.   

Abstract

Intracellular cAMP level and cAMP mediated responses are elevated when Leishmania are exposed to macrophage phagolysosome conditions (37 °C and pH 5.5). Phosphodiesterases play major role in cAMP regulation and in the present study we have cloned and characterized a 2.1 kb cytosolic isoform of phosphodiesterase from Leishmania donovani (LdPDED) which plays important role in cAMP homeostasis when the promastigotes are exposed to macrophage phagolysome conditions for converting to axenic amastigotes. Domain characterization suggested the presence of two pseudo-substrate sites similar to the ones present in the regulatory subunit of cAMP-dependent protein kinase A (PKA) and a putative PKA phosphorylation site at T(708) of C-terminus of LdPDED. Deletion constructs and site directed mutagenesis revealed the ability of LdPDED to interact with L. donovani PKA catalytic subunits (LdPKAC1 and LdPKAC2) resulting in inhibition of kinase activity in one hand and increase of phosphodiesterase activity through PKA mediated phosphorylation at putative phosphorylation site on the other hand. This study therefore identifies a unique phosphodiesterase in L. donovani which appears to regulate cAMP-dependent PKA signaling through a two way process.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  L. donovani; Phosphodiesterase; Phosphorylation; Protein kinase A; Psudosubstrate residues

Mesh:

Substances:

Year:  2014        PMID: 25310904     DOI: 10.1016/j.biocel.2014.10.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  1 in total

Review 1.  The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!

Authors:  Daniel N A Tagoe; Titilola D Kalejaiye; Harry P de Koning
Journal:  Front Pharmacol       Date:  2015-09-07       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.